117 related articles for article (PubMed ID: 38661582)
21. Novel Soluplus(®)-TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines.
Bernabeu E; Gonzalez L; Cagel M; Gergic EP; Moretton MA; Chiappetta DA
Colloids Surf B Biointerfaces; 2016 Apr; 140():403-411. PubMed ID: 26780253
[TBL] [Abstract][Full Text] [Related]
22. Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy.
Li B; Tan T; Chu W; Zhang Y; Ye Y; Wang S; Qin Y; Tang J; Cao X
Drug Deliv; 2022 Dec; 29(1):75-88. PubMed ID: 34964421
[TBL] [Abstract][Full Text] [Related]
23. SET protein overexpression contributes to paclitaxel resistance in MCF-7/S cells through PI3K/Akt pathway.
Zhang W; Zheng X; Meng T; You H; Dong Y; Xing J; Chen S
J Drug Target; 2017 Mar; 25(3):255-263. PubMed ID: 27718638
[TBL] [Abstract][Full Text] [Related]
24. Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines.
Wang Y; Yu L; Han L; Sha X; Fang X
Int J Pharm; 2007 Jun; 337(1-2):63-73. PubMed ID: 17289311
[TBL] [Abstract][Full Text] [Related]
25. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer.
Chang L; Hu Z; Zhou Z; Zhang H
Cell Physiol Biochem; 2018; 48(1):16-28. PubMed ID: 30001527
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of anti-tumor effects of crocin on a novel 3D tissue-engineered tumor model based on sodium alginate/gelatin microbead.
Zhu J; Zheng S; Liu H; Wang Y; Jiao Z; Nie Y; Wang H; Liu T; Song K
Int J Biol Macromol; 2021 Mar; 174():339-351. PubMed ID: 33529625
[TBL] [Abstract][Full Text] [Related]
27. Carbonic anhydrase 12 gene silencing reverses the sensitivity of paclitaxel in drug-resistant breast cancer cells.
Huang T; Tang L; Wang H; Lin L; Fu J
Bioengineered; 2021 Dec; 12(2):9806-9818. PubMed ID: 34696661
[TBL] [Abstract][Full Text] [Related]
28. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
Baek JS; Cho CW
J Pharm Pharmacol; 2013 Jan; 65(1):72-8. PubMed ID: 23215690
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer.
Li Y; Zhang L; Dong Z; Xu H; Yan L; Wang W; Yang Q; Chen C
Pathol Res Pract; 2021 Apr; 220():153405. PubMed ID: 33756128
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel-betulinic acid hybrid nanosuspensions for enhanced anti-breast cancer activity.
Wang R; Yang M; Li G; Wang X; Zhang Z; Qiao H; Chen J; Chen Z; Cui X; Li J
Colloids Surf B Biointerfaces; 2019 Feb; 174():270-279. PubMed ID: 30469048
[TBL] [Abstract][Full Text] [Related]
31. Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
Sootichote R; Thuwajit P; Singsuksawat E; Warnnissorn M; Yenchitsomanus PT; Ithimakin S; Chantharasamee J; Thuwajit C
BMC Cancer; 2018 Feb; 18(1):231. PubMed ID: 29486738
[TBL] [Abstract][Full Text] [Related]
32. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
33. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression.
Pan W; Wang Q; Zhang Y; Zhang N; Qin J; Li W; Wang J; Wu F; Cao L; Xu G
Cell Physiol Biochem; 2016; 39(2):481-90. PubMed ID: 27383277
[TBL] [Abstract][Full Text] [Related]
34. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel.
Zhao W; Song Y; Xu B; Zhan Q
Cancer Biol Ther; 2012 Feb; 13(3):156-63. PubMed ID: 22353935
[TBL] [Abstract][Full Text] [Related]
37. Short-term hyperthermia promotes the sensitivity of MCF-7 human breast cancer cells to paclitaxel.
Lin Y; Liu Z; Li Y; Liao X; Liao S; Cen S; Yang L; Wei J; Hu X
Biol Pharm Bull; 2013; 36(3):376-83. PubMed ID: 23229357
[TBL] [Abstract][Full Text] [Related]
38. Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.
Chen SY; Hu SS; Dong Q; Cai JX; Zhang WP; Sun JY; Wang TT; Xie J; He HR; Xing JF; Lu J; Dong YL
Asian Pac J Cancer Prev; 2013; 14(10):6135-40. PubMed ID: 24289639
[TBL] [Abstract][Full Text] [Related]
39. Resveratrol enhances chemosensitivity of renal cell carcinoma to paclitaxel.
Jie KY; Wei CL; Min Z; Ping GJ; Ying W; Dan Z; Sen Z
Front Biosci (Landmark Ed); 2019 Jun; 24(8):1452-1461. PubMed ID: 31136990
[TBL] [Abstract][Full Text] [Related]
40. Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells.
Chowdhury P; Nagesh PKB; Hatami E; Wagh S; Dan N; Tripathi MK; Khan S; Hafeez BB; Meibohm B; Chauhan SC; Jaggi M; Yallapu MM
J Colloid Interface Sci; 2019 Feb; 535():133-148. PubMed ID: 30292104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
